[ad_1]
In Brief:
There is bipartisan consensus that drugs in the U.S. cost a lot more than in other high-income countries; therefore, it is important to comprehend how governmental interventions in other nations can inform U.S. policy. Recent research on this topic has shed valuable light on the unique market conditions of drugs, including information asymmetries, insurance-mediated demand, and the role of patents in incentivizing innovation.
To intervene constructively in drug markets, it is important to recognize that such markets deviate from perfectly competitive markets due to four salient factors. First, drugs are “credence goods” which means that their quality and efficacy are difficult for consumers to assess, necessitating regulatory oversight by, for instance, the U.S. Food and Drug Administration or the European Medicines Agency to ensure safety and efficacy. Second, there are high development costs. Developing new drugs is expensive but imitation is relatively easy once a drug is approved. In addition, patents and exclusive rights protect innovators but they can also limit free entry into the market.
Third, consider the issue of insurance and moral hazard. The availability of insurance reduces price sensitivity among patients, thereby leading to higher consumption and enabling manufacturers to set higher prices, especially when they hold market power due to patents. Finally, one must account for the role played by the drug prescribing physicians who often display little sensitivity to the cost of drugs.
Governments in other nations have used several approaches to regulate drug prices and thereby address the issues created by the above factors. First, there is cost-based pricing. This means that some countries such as the U.K.’s pharmaceutical price regulation scheme use “cost-plus” regulations which seek to tie drug prices to development costs. However, this approach risks rewarding inefficiency and lacks a link to the therapeutic value of drugs.
Second, there is value-based pricing. This approach ties prices to a drug’s therapeutic benefits. While theoretically appealing, the approach requires robust health technology assessments to measure the clinical value of drugs. These assessments may be inconsistently applied across nations.
Third, we have cost-effectiveness thresholds that are used in the U.K. and Germany. These thresholds evaluate drugs by their cost per quality-adjusted life year (QALY). Drugs are reimbursed only if they meet a defined threshold. This approach limits moral hazard and provides clearer signals for investment but depends heavily on accurate data and value-of-life assumptions.
Fourth, there is reference pricing. In internal reference pricing, the idea is to set reimbursement levels based on the prices of similar drugs within the same country, thereby encouraging competition but potentially limiting innovation. In contrast, in external reference pricing, drug prices are based on prices in other nations. While this approach promotes fairness, the approach can lead to delays in launching new drugs in low-price countries to prevent triggering lower prices in higher-revenue markets. Finally, parallel trade allows the reimportation of drugs from low-price markets, but this can reduce access in those markets and disrupt global pricing strategies.
What does the use of these five approaches in other nations mean for the U.S.? The simple point is that the U.S. faces unique challenges in adopting these approaches. Why? For starters, consider the decentralized system in the U.S. Unlike countries with single-payer systems, the U.S. relies on private insurers and pharmacy benefit managers (PBMs) to negotiate prices, but this reliance prioritizes profits over social welfare.
Next there is the issue of Medicare drug price negotiation: The Inflation Reduction Act of 2022 introduced Medicare price negotiations. Although the objective here is to reduce costs, the policy could produce unintended consequences, such as delayed product launches or reduced generic competition. Moreover, given the global weight of the U.S. market—accounting for a significant share of pharmaceutical revenues—any change in U.S. pricing policy could shift global innovation incentives.
Owing to these problems, the research under discussion focuses on innovative solutions to balance the issues of drug access and drug innovation. A key solution is what is referred to as advance market commitments. The idea here is that payers commit to purchasing a drug, meeting specified criteria before development, as seen in Operation Warp Speed for COVID-19 vaccines. This reduces hold-up risk but requires precise criteria and international coordination.
A second possible solution is what is known as subscription pricing. Payers pay a fixed fee for unlimited drug access, and there are pay-for-performance contracts, where drug reimbursement depends on real-world treatment outcomes. This kind of approach offers budget predictability and better alignment of price with value, but it requires sophisticated monitoring and faces implementation hurdles.
Despite high drug prices, it is worth noting that pharmaceuticals are not the primary driver of overall healthcare cost growth in the U.S. Other factors such as high salaries for healthcare professionals contribute significantly. Therefore, we need to comprehend that while regulatory interventions can address market inefficiencies, policymakers must carefully balance static benefits (lower prices) with dynamic benefits (continued innovation).
While other countries offer valuable lessons, the U.S. must tailor policies to its unique market structure and global responsibilities. Effective solutions should prioritize aligning prices with therapeutic value, reducing information asymmetries, and fostering innovation while ensuring access. The challenge lies in designing policies that achieve these goals without unintended consequences, such as reduced investment in critical therapies.
Amit Batabyal is a distinguished professor, the Arthur J. Gosnell professor of economics, and the head of the Sustainability Department, all at the Rochester Institute of Technology but these views are his own.
[ad_2]
Opinion
Source link